Gadd M A, Casper E S, Woodruff J M, McCormack P M, Brennan M F
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York.
Ann Surg. 1993 Dec;218(6):705-12. doi: 10.1097/00000658-199312000-00002.
The authors reviewed a series of adult patients with extremity soft tissue sarcoma to determine the incidence of pulmonary metastases and outcome after treatment.
Of 716 patients admitted between January 1983 and December 1990, 135 (19%) had isolated pulmonary metastases as the initial site of distant recurrence. Fifty-eight percent (78 of 135) of the patients were treated surgically, and 83% of them had their tumors completely resected.
The median survival after complete resection was 19 months; incomplete resection, 10 months; and no operation, 8 months (p = 0.005). The 3-year survival rate after complete resection was 23%, compared with a 2% rate (1 of 57) in those treated nonsurgically (p < 0.001). Factors associated with an increased risk of pulmonary metastases included high tumor grade, tumor size greater than 5 cm, lower extremity site, and histologic type (spindle cell, tendosynovial, and extraskeletal osteosarcoma). Factors associated with complete resectability were the histologic types of spindle cell and extraskeletal osteosarcoma.
Complete surgical resection remains the only possibility for cure from pulmonary metastases in soft tissue sarcoma; however, only 11% of the 19% of patients with an extremity sarcoma whose first distant recurrence is in the lung will be alive at 3 years, despite therapy. Complete resection and the development of more effective adjuvant treatments are imperative to improve outcome for this group of patients.
作者回顾了一系列成年肢体软组织肉瘤患者,以确定肺转移的发生率及治疗后的预后情况。
在1983年1月至1990年12月期间收治的716例患者中,135例(19%)以孤立性肺转移作为远处复发的初始部位。58%(135例中的78例)的患者接受了手术治疗,其中83%的患者肿瘤被完全切除。
完全切除后的中位生存期为19个月;不完全切除为10个月;未手术为8个月(p = 0.005)。完全切除后的3年生存率为23%,相比之下,非手术治疗患者的3年生存率为2%(57例中的1例)(p < 0.001)。与肺转移风险增加相关的因素包括肿瘤分级高、肿瘤大小大于5 cm、下肢部位以及组织学类型(梭形细胞、腱鞘滑膜和骨外骨肉瘤)。与完全可切除性相关的因素是梭形细胞和骨外骨肉瘤的组织学类型。
完全手术切除仍然是软组织肉瘤肺转移治愈的唯一可能性;然而,在肢体肉瘤患者中,首发远处复发在肺部的患者中,尽管接受了治疗,但3年后只有11%的患者存活。完全切除以及开发更有效的辅助治疗对于改善这组患者的预后至关重要。